Dabur India Limited

Dabur India Limited, established in 1884 by Dr. S.K. Burman in Kolkata, India, has evolved into a leading multinational consumer goods company specializing in Ayurvedic and natural health care products. The company is headquartered in Ghaziabad, Uttar Pradesh, and operates under the Corporate Identification Number (CIN) L24230UP1986PLC008119. As of March 2020, Dabur employed approximately 7,740 individuals. In the fiscal year ending March 31, 2025, Dabur reported revenues of approximately $1.5 billion, reflecting a 1.3% increase from the previous year. The company's diverse product portfolio includes health supplements, digestive products, hair care, oral care, skin care, home care, and food & beverages, marketed under well-known brands such as Dabur Chyawanprash, Dabur Honey, Dabur Amla, and Real.

Dabur India Limited operates a comprehensive manufacturing network spanning nine countries, including India, the UAE, Nepal, Bangladesh, Sri Lanka, South Africa, Nigeria, Egypt, and Turkey. This extensive network ensures the efficient production and distribution of its products across 120+ countries. In January 2024, the company approved an investment of ₹135 crore to establish a new manufacturing facility in South India, marking its first plant in the region. This facility is expected to produce a range of Dabur's Ayurvedic healthcare, personal care, and home care products, including Dabur Honey, Dabur Red Paste, and Odonil air fresheners.

Dabur India Limited is led by a team of experienced executives. Mohit Malhotra serves as the Chief Executive Officer (CEO) and Whole Time Director, overseeing the company's global operations. Ankush Jain holds the position of Chief Financial Officer (CFO), responsible for managing the company's financial strategies and operations. Pritam Das Narang serves as the Group Director of Corporate Affairs and Whole Time Director, focusing on corporate governance and strategic initiatives.

Dabur India Limited has established a significant presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company exports a diverse range of finished pharmaceutical formulations, including extracts, arishta, churna, asava, and bhasma, primarily in the Ayurvedic and herbal product categories. In the fiscal year 2022-2026, Dabur's total export value was $1.9 million USD, with 830 shipments across six products in one therapeutic category. The top five exported products were extract ($1.1 million, 9.0% market share), arishta ($590,000, 41.0% market share), churna ($111,000, 6.2% market share), asava ($61,000, 13.4% market share), and bhasma ($34,000, 8.2% market share). The company's portfolio concentration is high, with the top five products accounting for 98.3% of the total export value. Dabur's strong market position in these categories underscores its commitment to quality and regulatory compliance in these regions.

Dabur India Limited has strategically expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 120 countries, with significant presence in the Middle East, SAARC countries, Africa, the US, Europe, and Russia. Dabur's commitment to quality and adherence to international standards have facilitated its entry into these markets, enabling the company to cater to diverse consumer needs and preferences.

Dabur India Limited's geographic strategy focuses on diversification to mitigate concentration risk and capitalize on growth opportunities across various regions. The company's extensive manufacturing network across nine countries and its presence in over 120 countries reflect a deliberate approach to market expansion. By establishing manufacturing facilities in key regions, such as the recent investment in South India, Dabur aims to enhance its supply chain efficiency and better serve local markets. This strategic direction aligns with Dabur's mission to make Ayurveda relevant for the new generation and to be present in every household.

Dabur India Limited has made significant strides in the U.S. market, particularly in the dietary supplements segment. The company has established FDA facility registrations for its manufacturing plants, ensuring compliance with U.S. regulations. Dabur's products are manufactured in facilities that adhere to Good Manufacturing Practices (GMP), and the company has filed Abbreviated New Drug Applications (ANDAs) for certain products. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, Dabur's commitment to quality and regulatory compliance is evident in its operations.

Dabur India Limited's manufacturing facilities are certified for compliance with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards. These certifications reflect the company's adherence to international quality standards, ensuring the safety and efficacy of its products. Dabur's commitment to quality is further demonstrated by its extensive research and development efforts, which have led to the launch of new products such as the SIENS range of digital-first wellness products in June 2025.

Dabur India Limited operates in compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations and holds the necessary manufacturing licenses and approvals from state drug controllers. The company has obtained export No Objection Certificates (NOCs) for its products, facilitating international trade. Dabur's adherence to CDSCO guidelines ensures that its products meet the required quality and safety standards for both domestic and international markets.

As of March 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued to Dabur India Limited by regulatory authorities. This indicates the company's strong compliance record and commitment to maintaining high-quality standards across its operations.

Dabur India Limited faces competition from several key players in the Ayurvedic and natural health care segment, including Himalaya Drug Company, Patanjali Ayurved, and Baidyanath. In the global market, competitors such as Himalaya and Patanjali have established significant market shares. Dabur's focus on quality, innovation, and extensive distribution network has enabled it to maintain a leading position in the industry. The company's diverse product portfolio and strong brand recognition contribute to its competitive edge.

Dabur India Limited's key differentiators include its extensive experience of over 140 years in the Ayurvedic and natural health care sector, a diverse product portfolio encompassing health supplements, personal care, and food & beverages, and a strong commitment to quality and innovation. The company's ability to blend traditional Ayurvedic knowledge with modern science allows it to develop products tailored to the specific needs of consumers across the globe.

Dabur India Limited's current strategic direction focuses on expanding its presence in both domestic and international markets, with a particular emphasis on emerging markets. The company's investment in new manufacturing facilities, such as the recent establishment in South India, reflects its commitment to meeting local demand and enhancing supply chain efficiency. Dabur's future outlook includes further diversification of its product portfolio, exploration of new market segments, and continued emphasis on research and development to drive growth and innovation.

Dabur India Limited has a strong track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $1.9 million USD and 830 shipments in the fiscal year 2022-2026. The company's portfolio concentration is high, with the top five products accounting for 98.3% of the total export value. Dabur's adherence to international quality standards, as evidenced by its WHO and EU GMP certifications, and its commitment to innovation and quality, make it a reliable supplier in the pharmaceutical industry.

Importers should verify the following certifications when considering Dabur India Limited as a supplier:

• FDA Facility Registration: Confirm that Dabur's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

• WHO-GMP Certification: Ensure that Dabur's facilities comply with World Health Organization Good Manufacturing Practices.

• EU GMP Certification: Verify that Dabur's manufacturing processes adhere to European Union Good Manufacturing Practices.